Nasal Spray Naloxone Gets Closer to Public Availability

Adapt Pharma Limited has begun a new drug application (NDA) with the FDA for a nasal spray form of naloxone, which is used in preventing opioid overdose deaths. This submission is a “rolling submission,” meaning that “completed portions . . . [will] be submitted and reviewed by the FDA on an ongoing basis” (NIDA, 2015).

According to the National Institute on Drug Abuse (NIDA), “the only current FDA-approved method of administering naloxone is by injection” (2015), so a nasal delivery system would allow for more widespread availability.

Adapt Pharma Limited is a partner of Lightlake Therapeutics, Inc., a biopharmaceutical company that develops new treatment for addiction. Lightlake Therapeutics has been partnered with NIDA since 2013.

References

National Institute on Drug Abuse (NIDA). (2015). Nasal spray naloxone step closer to public availability. Retrieved from http://www.drugabuse.gov/news-events/news-releases/2015/06/nasal-spray-naloxone-one-step-closer-to-public-availability